Organon & Co. (NYSE:OGN) Reaches New 52-Week High – What’s Next?

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week high on Monday . The company traded as high as $13.47 and last traded at $13.4550, with a volume of 536582 shares. The stock had previously closed at $13.40.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on OGN. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. BNP Paribas Exane reaffirmed a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Barclays upped their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Organon & Co. presently has an average rating of “Reduce” and an average price target of $11.40.

Organon & Co. Price Performance

The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. The stock has a market cap of $3.53 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 1.24 and a beta of 1.57. The business’s fifty day simple moving average is $8.74 and its 200 day simple moving average is $8.01.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the firm earned $1.02 EPS. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. Research analysts predict that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be issued a $0.02 dividend. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s payout ratio is currently 8.60%.

Insider Activity

In related news, SVP Lynette Holzbaur bought 26,448 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were acquired at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the purchase, the senior vice president owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors have recently modified their holdings of OGN. AQR Capital Management LLC raised its stake in shares of Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after purchasing an additional 3,650,860 shares in the last quarter. UBS Group AG raised its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Organon & Co. by 78.1% in the 1st quarter. First Trust Advisors LP now owns 3,227,320 shares of the company’s stock valued at $19,332,000 after purchasing an additional 1,415,239 shares in the last quarter. Finally, Private Management Group Inc. raised its stake in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.